Noemí Cerulla Torrente1, José-Blas Navarro Pastor2, Nuria de la Osa Chaparro3. 1. Memory Unit, Consorci Sanitari de Terrassa (CST), Brain, Cognition and Behaviour Research Group, Unitat d'Investigació Biomèdica UAB-CST (UIB), Terrassa, Barcelona, Spain. NCerulla@cst.cat. 2. Department of Psychobiology and Methodology of Behavioural Sciences, Universitat Autònoma de Barcelona (UAB), Cerdanyola del Vallès, Barcelona, Spain. 3. Department of Clinical and Health Psychology, Universitat Autònoma de Barcelona (UAB), Cerdanyola del Vallès, Barcelona, Spain.
Abstract
PURPOSE: The aim of this review is to provide an updated overview of chemotherapy-related cognitive impairment (CRCI) in patients with cancer outside central nervous system (CNS), its incidence and prevalence, the cognitive pattern in neuropsychological studies, neuroimaging findings, and the relationship between chemobrain and aging. Methodological limitations of studies are also discussed. METHODS: This review was guided by the PRISMA statement. The MEDLINE and Scopus databases were employed to search articles about CRCI in non-CNS cancer patients published from January 2004 to September 2019. Two types of research were reviewed: prospective studies addressing the effects of chemotherapy on cognition and systematic reviews about factors related with CRCI, also as neuroimaging findings and current available treatments. RESULTS: Fifty-nine studies meeting the criteria were analyzed: 47 were longitudinal studies on cancer and cognition and 12 were reviews on risk factors, neuroimaging, and treatment. The majority of studies find cognitive impairment in patients with cancer treated with chemotherapy. The body of the literature on breast cancer is the most abundant, but there are also studies on colorectal, testicular, and lung cancer. Neuroimaging studies show changes in structure and activation in patients undergoing chemotherapy. Non-pharmacological treatment is effective for improving cognition and quality of life. CONCLUSIONS: The occurrence of CRCI during the course of treatment in people with different types of cancer is frequent. Some risk factors have been identified, but CRCI is a complex phenomenon, with mediating factors related to cancer and treatment and moderating factors related with lifestyle and health. IMPLICATIONS FOR CANCER SURVIVORS: This review highlights the importance of recognizing that this cognitive dysfunction is frequent, mild to moderate in nature but with great impact on quality of life.
PURPOSE: The aim of this review is to provide an updated overview of chemotherapy-related cognitive impairment (CRCI) in patients with cancer outside central nervous system (CNS), its incidence and prevalence, the cognitive pattern in neuropsychological studies, neuroimaging findings, and the relationship between chemobrain and aging. Methodological limitations of studies are also discussed. METHODS: This review was guided by the PRISMA statement. The MEDLINE and Scopus databases were employed to search articles about CRCI in non-CNS cancerpatients published from January 2004 to September 2019. Two types of research were reviewed: prospective studies addressing the effects of chemotherapy on cognition and systematic reviews about factors related with CRCI, also as neuroimaging findings and current available treatments. RESULTS: Fifty-nine studies meeting the criteria were analyzed: 47 were longitudinal studies on cancer and cognition and 12 were reviews on risk factors, neuroimaging, and treatment. The majority of studies find cognitive impairment in patients with cancer treated with chemotherapy. The body of the literature on breast cancer is the most abundant, but there are also studies on colorectal, testicular, and lung cancer. Neuroimaging studies show changes in structure and activation in patients undergoing chemotherapy. Non-pharmacological treatment is effective for improving cognition and quality of life. CONCLUSIONS: The occurrence of CRCI during the course of treatment in people with different types of cancer is frequent. Some risk factors have been identified, but CRCI is a complex phenomenon, with mediating factors related to cancer and treatment and moderating factors related with lifestyle and health. IMPLICATIONS FOR CANCER SURVIVORS: This review highlights the importance of recognizing that this cognitive dysfunction is frequent, mild to moderate in nature but with great impact on quality of life.
Authors: Ana F Oliveira; Sofia Fernandes; Juliana D Reis; Ana Torres; Isabel M Santos; Diane Von Ah Journal: BMJ Open Date: 2022-07-12 Impact factor: 3.006
Authors: Annemarie C Eggen; Nadine M Richard; Ingeborg Bosma; Mathilde Jalving; Natasha B Leighl; Geoffrey Liu; Kenneth Mah; Randa Higazy; David B Shultz; Anna K L Reyners; Gary Rodin; Kim Edelstein Journal: Neurooncol Pract Date: 2021-09-07
Authors: Valentina E Di Mattei; Gaia Perego; Paola Taranto; Martina Mazzetti; Paola M V Rancoita; Francesca Milano; Giorgia Mangili; Emanuela Rabaiotti; Alice Bergamini; Raffaella Cioffi; Massimo Candiani Journal: Support Care Cancer Date: 2022-05-24 Impact factor: 3.359
Authors: Teresa Soria-Comes; Vicente Palomar-Abril; María Martín Ureste; Javier García Sánchez; Josefa Esperanza Marco Buades; María José Fernández Llavador; Amparo López Gabaldón; Mar González Jurado; Inmaculada Concepción Maestu Maiques Journal: Transl Cancer Res Date: 2020-11 Impact factor: 1.241